Anti-Rat CD28 Antibody (JJ319) 

Anti-Rat CD28 Antibody (JJ319) is a mouse-derived IgG1 κ type antibody inhibitor, targeting to rat CD28. Anti-Rat CD28 Antibody (JJ319) activates T cells in the presence of T cell receptor-stimulation. Anti-Rat CD28 Antibody (JJ319) can be used for the researches of inflammation and immunology, such as transplantation and neuritis^[1][2].

Mouse IgG1 kappa

Mouse IgG1 kappa, Isotype Control

Rat

CD28

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Rat CD28 Antibody (JJ319) (4 mg/kg, 4 days prior to transplantation) prolongs graft survival in combination with donor-specific blood transfusion treatment in rat liver transplantation models^[1].
Anti-Rat CD28 Antibody (JJ319) (1 mg, i.p., at day 0 and day 12) reduces disease severity in experimental autoimmune neuritis rats models^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

25660  [NCBI]

P31042

in vitro T cell stimulation/activation; Flow cytometry

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

[Anti-Rat CD28 Antibody (JJ319)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Product Image

• [1]. Urakami H, et al. Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc. 2006 Dec;38(10):3244-6.  [Content Brief]

  [2]. Schmidt J, et al. Treatment and prevention of experimental autoimmune neuritis with superagonistic CD28-specific monoclonal antibodies. J Neuroimmunol. 2003 Jul;140(1-2):143-52.  [Content Brief]